Commonwealth Equity Services LLC Raises Position in Altimmune, Inc. (NASDAQ:ALT)

Commonwealth Equity Services LLC grew its position in Altimmune, Inc. (NASDAQ:ALTFree Report) by 31.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,945 shares of the company’s stock after acquiring an additional 19,172 shares during the period. Commonwealth Equity Services LLC owned about 0.11% of Altimmune worth $814,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ALT. Timelo Investment Management Inc. boosted its holdings in shares of Altimmune by 2,597.0% in the fourth quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company’s stock valued at $9,102,000 after acquiring an additional 779,095 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in Altimmune during the fourth quarter worth about $4,493,000. Gerber LLC purchased a new stake in Altimmune during the fourth quarter worth about $2,878,000. Sectoral Asset Management Inc. purchased a new stake in Altimmune during the fourth quarter worth about $1,922,000. Finally, Pennant Investors LP purchased a new stake in Altimmune during the fourth quarter worth about $1,235,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Price Performance

NASDAQ:ALT opened at $6.90 on Wednesday. The firm has a 50 day simple moving average of $7.04 and a 200-day simple moving average of $8.75. The firm has a market cap of $489.21 million, a PE ratio of -4.34 and a beta of 0.13. Altimmune, Inc. has a 1-year low of $2.09 and a 1-year high of $14.84.

Altimmune (NASDAQ:ALTGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. During the same period in the prior year, the firm earned ($0.40) EPS. As a group, sell-side analysts expect that Altimmune, Inc. will post -1.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective on shares of Altimmune in a report on Friday, June 21st. B. Riley reaffirmed a “buy” rating and issued a $20.00 price target on shares of Altimmune in a report on Tuesday, June 25th. JMP Securities reduced their price target on shares of Altimmune from $25.00 to $24.00 and set a “market outperform” rating on the stock in a report on Friday, May 10th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Tuesday, May 14th. Finally, Guggenheim downgraded shares of Altimmune from a “buy” rating to a “neutral” rating in a report on Monday, April 29th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Altimmune currently has a consensus rating of “Moderate Buy” and an average price target of $18.80.

Check Out Our Latest Stock Report on ALT

Altimmune Profile

(Free Report)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

Featured Stories

Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALTFree Report).

Institutional Ownership by Quarter for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.